Clinical trials: Myasthenia Gravis, Generalized, open to volunteers
Generalized Myasthenia Gravis, Anti-AChR Antibody Positive
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
- Trial name
- NCT06967480
- Testing
- Ravulizumab
- Where
- 23 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis (gMG)
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
- Trial name
- NCT06359041
- Testing
- CABA-201
- Where
- 17 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cabaletta Bio
Myasthenia Gravis, MG
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis.
- Conditions
- Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis
- Trial name
- NCT07294170
- Testing
- Efgartigimod IV, Empasiprubart IV, Efgartigimod PH20 SC PFS
- Where
- 37 sites in United States, Belgium and 6 more
- Volunteers
- 70 people
- Sponsor
- argenx
Myasthenia Gravis Generalised
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
The goal of this observational study is to learn if computer analysis of voice recordings can detect a type of exhaustion called "central fatigue" in adults with generalised myasthenia gravis.
- Trial name
- NCT07033559
- Volunteers
- 240 people
- Sponsor
- Thymia Limited
Myasthenia Gravis
Efgartigimod for Consolidation Therapy in gMG
The goal of this observational study is to evaluate the efficacy and safety of consolidation therapy with corticosteroids and/or immunosuppressants combined with efgartigimod in patients with generalized myasthenia gravis after…
- Trial name
- NCT07079020
- Volunteers
- 130 people
- Sponsor
- Da, Yuwei, M.D.
Myasthenia Gravis (MG)
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
Myasthenia Gravis (MG) is a chronic autoimmune disease mediated by pathogenic antibodies. Approximately 10%-15% of patients present with refractory status, defined as having an inadequate response to existing therapies or an…
- Trial name
- NCT07499323
- Testing
- Talquetamab
- Volunteers
- 2 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Generalized Myasthenia Gravis
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
- Trial name
- NCT07039916
- Testing
- IMVT-1402
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 231 people
- Sponsor
- Immunovant Sciences GmbH
Generalized Myasthenia Gravis (gMG)
Zilucoplan for Severe gMG Exacerbations
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks.
- Trial name
- NCT07215949
- Testing
- Zilucoplan®
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Miriam Freimer
Myasthenia Gravis
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of CD19-BCMA CAR-T in the treatment of refractory, generalized myasthenia gravis.
- Trial name
- NCT06371040
- Testing
- CD19-BCMA Targeted CAR-T Dose 1, CD19-BCMA Targeted CAR-T Dose 2
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Ting Chang, MD
Generalized Myasthenia Gravis, gMG
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
The purpose of this trial is to evaluate the long-term safety of efgartigimod IV and efgartigimod PH20 SC administered to participants with gMG in the antecedent studies, ARGX-113-2006 and ARGX-113-2207, respectively.
- Trial name
- ADAPT Jr + (NCT05374590)
- Testing
- Efgartigimod IV or Efgartigimod PH20 SC
- Where
- 17 sites in United States, Belgium and 8 more
- Volunteers
- 12 people
- Sponsor
- argenx
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of…
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
- Trial name
- NCT06312644
- Testing
- Ultomiris
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on neuromuscular junction (NMJ) transmission and fatigability in adults with Generalized…
- Trial name
- NCT06064695
- Testing
- Whole-body Electrical Muscle Stimulation Exercise
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Myasthenia Gravis, Generalized
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT07647510
- Testing
- Claseprubart
- Where
- 12 sites in United States, Georgia and 1 more
- Volunteers
- 195 people
- Sponsor
- Dianthus Therapeutics
Generalized Myasthenia Gravis
Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)
Generalized Myasthenia Gravis (gMG) is a rare autoimmune disease (a disease in which the body attacks its own tissues) that causes muscle weakness and significant fatigue.
- Trial name
- REAL MG PRO (NCT07570589)
- Testing
- Patients diagnosed with generalized myasthenia gravis and treated with Rozanolixizumab
- Where
- 11 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Myasthenia Gravis, Generalized
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
Generalized Myasthenia Gravis (gMG) is a rare chronic autoimmune disorder causing muscle weakness and fatigue, primarily due to autoantibodies that disrupt neuromuscular junction function.
- Trial name
- OPTIMAGE (NCT07072988)
- Testing
- Efgartigimod
- Where
- 9 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Generalized Myasthenia Gravis
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.
- Trial name
- NCT07215650
- Testing
- Cizutamig
- Where
- 10 sites in China
- Volunteers
- 44 people
- Sponsor
- Candid Therapeutics
Myasthenia Gravis, Generalized
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
- Trial name
- tMG (NCT05067348)
- Testing
- Tocilizumab Injectable Product
- Where
- 6 sites in China
- Volunteers
- 64 people
- Sponsor
- Tang-Du Hospital
Rare Diseases, Generalized Myasthenia Gravis (gMG)
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR)…
- Trial name
- NCT07247279
- Where
- 7 sites in Russia
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Myasthenia Gravis (MG)
Sexual and Urinary Dysfunctions in Generalized Myasthenia
Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that disrupt the function of the neuromuscular junction.
- Trial name
- MYAOUS (NCT07677852)
- Testing
- No intervetion
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative